U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H26F6N2O2
Molecular Weight 500.4766
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROLAPITANT

SMILES

C[C@@H](OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)C3=CC=CC=C3)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F

InChI

InChIKey=FIVSJYGQAIEMOC-ZGNKEGEESA-N
InChI=1S/C25H26F6N2O2/c1-16(17-11-19(24(26,27)28)13-20(12-17)25(29,30)31)35-15-23(18-5-3-2-4-6-18)10-9-22(14-32-23)8-7-21(34)33-22/h2-6,11-13,16,32H,7-10,14-15H2,1H3,(H,33,34)/t16-,22-,23-/m1/s1

HIDE SMILES / InChI
Molecular Formula C25H26F6N2O2
Molecular Weight 500.4766
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Rolapitant (VARUBI) is neurokinin 1 (NK1) receptor antagonist. Rolapitant does not have significant affinity for the NK2 or NK3 receptors. Drug is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Most common adverse reactions are: neutropenia and hiccups at Cisplatin Based Highly Emetogenic Chemotherapy; decreased appetite, neutropenia and dizziness at Moderately Emetogenic Chemotherapy and Combinations of Anthracycline and Cyclophosphamide. Inhibition of BCRP and P-gp by rolapitant can increase plasma concentrations of the concomitant drug and potential for adverse reactions. Strong CYP3A4 Inducers (e.g., rifampin) can significantly reduce plasma concentrations of rolapitant and decrease the efficacy of VARUBI.

CNS Activity

Originator

Approval Year

2015
471
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
 0.42 nM [Ki]
Binding Agent
1064
 20.0 µM [IC50]
Binding Agent
1064
 4.05 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Approved
8429
VARUBI

Approved Use

VARUBI™ is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. VARUBI is a substance P/neurokinin 1 (NK1) receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. ( 1 )

Launch Date

2015
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
967.69 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/28906561
180 mg single, oral
dose: 180 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROLAPITANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
968 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208399s000lbl.pdf
180 mg single, oral
dose: 180 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROLAPITANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
118019.42 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/28906561
180 mg single, oral
dose: 180 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROLAPITANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
183 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208399s000lbl.pdf
180 mg single, oral
dose: 180 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROLAPITANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
20 mg single, intravenous
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 21 yeras
n = 1
Health Status: healthy
Age Group: 21 yeras
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Disc. AE: Nausea, Retching...
AEs leading to
discontinuation/dose reduction:
Nausea (moderate, 1 patient)
Retching (moderate, 1 patient)
Cough (moderate, 1 patient)
Hyperhidrosis (moderate, 1 patient)
Abdominal pain (mild, 1 patient)
Dry mouth (mild, 1 patient)
Dyspnea (mild, 1 patient)
Visual impairment (mild, 1 patient)
Feeling hot (mild, 1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
300 mg single, intravenous
Highest studied dose
Dose: 300 mg
Route: intravenous
Route: single
Dose: 300 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 23 years
n = 1
Health Status: healthy
Age Group: 23 years
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Disc. AE: Back pain, Dizziness...
AEs leading to
discontinuation/dose reduction:
Back pain (mild, 1 patient)
Dizziness (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
720 mg single, oral
Studied dose
Dose: 720 mg
Route: oral
Route: single
Dose: 720 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/30256537
healthy, 26 years
n = 6
Health Status: healthy
Age Group: 26 years
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/30256537
Sources:
https://pubmed.ncbi.nlm.nih.gov/30256537
200 mg single, oral
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/21385988
unhealthy, 47.4 years
n = 104
Health Status: unhealthy
Age Group: 47.4 years
Sex: F
Population Size: 104
Sources:
https://pubmed.ncbi.nlm.nih.gov/21385988
Sources:
https://pubmed.ncbi.nlm.nih.gov/21385988
200 mg single, intravenous
Dose: 200 mg
Route: intravenous
Route: single
Dose: 200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 54 yeras
n = 1
Health Status: healthy
Age Group: 54 yeras
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Disc. AE: Abdominal discomfort, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Abdominal discomfort (mild, 1 patient)
Diarrhea (mild, 1 patient)
Presyncope (mild, 1 patient)
Feeling hot (mild, 1 patient)
Headache (mild, 1 patient)
Dizziness (mild, 1 patient)
Dry mouth (mild, 1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
AEs

AEs

AESignificanceDosePopulation
Abdominal pain mild, 1 patient
Disc. AE
20 mg single, intravenous
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 21 yeras
n = 1
Health Status: healthy
Age Group: 21 yeras
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Dry mouth mild, 1 patient
Disc. AE
20 mg single, intravenous
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 21 yeras
n = 1
Health Status: healthy
Age Group: 21 yeras
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Dyspnea mild, 1 patient
Disc. AE
20 mg single, intravenous
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 21 yeras
n = 1
Health Status: healthy
Age Group: 21 yeras
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Feeling hot mild, 1 patient
Disc. AE
20 mg single, intravenous
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 21 yeras
n = 1
Health Status: healthy
Age Group: 21 yeras
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Visual impairment mild, 1 patient
Disc. AE
20 mg single, intravenous
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 21 yeras
n = 1
Health Status: healthy
Age Group: 21 yeras
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Cough moderate, 1 patient
Disc. AE
20 mg single, intravenous
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 21 yeras
n = 1
Health Status: healthy
Age Group: 21 yeras
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Hyperhidrosis moderate, 1 patient
Disc. AE
20 mg single, intravenous
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 21 yeras
n = 1
Health Status: healthy
Age Group: 21 yeras
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Nausea moderate, 1 patient
Disc. AE
20 mg single, intravenous
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 21 yeras
n = 1
Health Status: healthy
Age Group: 21 yeras
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Retching moderate, 1 patient
Disc. AE
20 mg single, intravenous
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 21 yeras
n = 1
Health Status: healthy
Age Group: 21 yeras
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Dizziness 1 patient
Disc. AE
300 mg single, intravenous
Highest studied dose
Dose: 300 mg
Route: intravenous
Route: single
Dose: 300 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 23 years
n = 1
Health Status: healthy
Age Group: 23 years
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Back pain mild, 1 patient
Disc. AE
300 mg single, intravenous
Highest studied dose
Dose: 300 mg
Route: intravenous
Route: single
Dose: 300 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 23 years
n = 1
Health Status: healthy
Age Group: 23 years
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Abdominal discomfort mild, 1 patient
Disc. AE
200 mg single, intravenous
Dose: 200 mg
Route: intravenous
Route: single
Dose: 200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 54 yeras
n = 1
Health Status: healthy
Age Group: 54 yeras
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Diarrhea mild, 1 patient
Disc. AE
200 mg single, intravenous
Dose: 200 mg
Route: intravenous
Route: single
Dose: 200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 54 yeras
n = 1
Health Status: healthy
Age Group: 54 yeras
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Dizziness mild, 1 patient
Disc. AE
200 mg single, intravenous
Dose: 200 mg
Route: intravenous
Route: single
Dose: 200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 54 yeras
n = 1
Health Status: healthy
Age Group: 54 yeras
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Dry mouth mild, 1 patient
Disc. AE
200 mg single, intravenous
Dose: 200 mg
Route: intravenous
Route: single
Dose: 200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 54 yeras
n = 1
Health Status: healthy
Age Group: 54 yeras
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Feeling hot mild, 1 patient
Disc. AE
200 mg single, intravenous
Dose: 200 mg
Route: intravenous
Route: single
Dose: 200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 54 yeras
n = 1
Health Status: healthy
Age Group: 54 yeras
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Headache mild, 1 patient
Disc. AE
200 mg single, intravenous
Dose: 200 mg
Route: intravenous
Route: single
Dose: 200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 54 yeras
n = 1
Health Status: healthy
Age Group: 54 yeras
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Presyncope mild, 1 patient
Disc. AE
200 mg single, intravenous
Dose: 200 mg
Route: intravenous
Route: single
Dose: 200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
healthy, 54 yeras
n = 1
Health Status: healthy
Age Group: 54 yeras
Sex: M
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf
Page: p. 30
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737

inhibitor
1587
inhibitor
1767
inhibitor
1852
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
BCRP
699

P-gp
1461

CYP1A2
1524

CYP2E1
882

CYP2A6
707

CYP2B6
810

CYP2C8
911

CYP2C19
1478

CYP3A4/5
278

BSEP
402
P-gp
1537

OATP1B1
406

OATP1B3
350

CYP2J2
56

CYP2B6
664

CYP2C8
693
CYP1A2
701

CYP2C8
168

CYP2C19
293

CYP3A4/5
124

CYP2B6
547
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1692
 no [IC50 >100 uM]
CYP2E1
970
 no [IC50 >100 uM]
CYP2B6
1001
 no
CYP2C8
965
 no
BCRP
773
 yes [IC50 0.172 uM]
yes (co-administration study)
Comment: Concomitant rolapitant increased the systemic exposure to sulfasalazine, a substrate of BCRP by 2.3-fold on Day 1 and the inhibitory effect was decreased on Day 7.
Page: 6.0
CYP2B6
1001
 yes [IC50 13 uM]
no (co-administration study)
Comment: No significant effects of rolapitant on PK of efavirenz were observed on Day 1 while a weak inhibition of efavirenz, a CYP2B6 substrate metabolism was noted on Day 7.
Page: 31.0
CYP2A6
739
 yes [IC50 22 uM]
CYP2C8
965
 yes [IC50 23 uM]
no (co-administration study)
Comment: Single-dose rolapitant resulted in a slight increase in Cmax and AUC of repaglinide, a CYP2C8 substrate by 29% and 24%, respectively on 7 days after rolapitant dosing while did not significantly affect the systemic exposure on Day 1.
Page: 31.0
CYP3A4
1925
 yes [IC50 41 uM]
CYP3A4/5
335
 yes [IC50 49 uM]
CYP2B6
1001
 yes [IC50 8.65 uM]
SCH 720881
3
CYP2C19
1553
 yes [IC50 8.7 uM]
unlikely (co-administration study)
Comment: Single-dose administration of rolapitant with omeprazole resulted in an increase in Cmax and AUCi of omeprazole by 44% and 23%, respectively on Day 1 compared to those after omeprazole alone. On Day 7, Cmax and AUCi of omeprazole was 37% and 15% higher, respectively.
Page: 31.0
CYP2C9
1819
 yes [IC50 9.6 uM]
CYP2D6
1891
 yes [Ki 3.4 uM]
BSEP
403
 yes
CYP1A2
1692
 yes
CYP2C19
1553
 yes
CYP3A4/5
335
 yes
P-gp
1650
 yes
yes (co-administration study)
Comment: Concomitant rolapitant increased the systemic exposure to sulfasalazine, a substrate of BCRP by 2.3-fold on Day 1 and the inhibitory effect was decreased on Day 7.
Page: 6.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
OATP1B1
406
 no
OATP1B3
350
 no
P-gp
1537
 no
CYP2B6
664
 yes
CYP2C8
693
 yes
CYP2J2
56
 yes
CYP3A4
1737
 yes
yes (co-administration study)
Comment: Rolapitant is not recommended in patients who are on a strong CYP3A4 inducer such as rifampin for the potential loss of efficacy due to a significant decrease in systemic exposure i.e. AUC decreased by 87% with concurrent rifampin. Concurrent ketoconazole, a strong CYP3A4 inhibitor did not significantly affect systemic exposure to rolapitant.
Page: 6.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:90908
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:90908
ChemicalBook
CB12628366
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB12628366
MolPort
MolPort-035-942-975
https://www.molport.com/shop/molecule-link/MolPort-035-942-975
ZINC
ZINC000003816514
http://zinc15.docking.org/substances/ZINC000003816514
PubMed

PubMed

TitleDatePubMed
Management of postoperative nausea and vomiting: focus on palonosetron.
2009 Feb
Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets.
2012 Jul
Rolapitant: first global approval.
2015 Nov
Patents

Patents

JP2013216694A
3
JP5352446B2
3

Sample Use Guides

In Vivo Use Guide
The recommended dosage is 180 mg rolapitant administered approximately 1 to 2 hours prior to the start of chemotherapy. Administer in combination with dexamethasone and a 5-HT3 receptor. antagonist
Route of Administration: Oral
In Vitro Use Guide
In vitro rolapitant and its metabolite M19 weakly inhibited hERG (potassium) current in Mouse L-929 cells stably transfected with human hERG, with an IC50 of 1.05 uM and 5.8 uM, respectively.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:34:23 GMT 2023
Edited
by admin
on Fri Dec 15 15:34:23 GMT 2023
Record UNII
NLE429IZUC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ROLAPITANT
DASH   INN   USAN   WHO-DD  
INN   USAN  
Official Name English
(5S,8S)-8-{[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]methyl}-8-phenyl-1,7-diazaspiro[4.5]decan-2-one
Systematic Name English
ROLAPITANT [USAN]
Common Name English
ROLAPITANT [MI]
Common Name English
Rolapitant [WHO-DD]
Common Name English
1,7-DIAZASPIRO(4.5)DECAN-2-ONE, 8-(((1R)-1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHOXY)METHYL)-8-PHENYL-, (5S,8S)-
Systematic Name English
rolapitant [INN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175786
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
WHO-ATC A04AD14
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
NCI_THESAURUS C267
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
Code System Code Type Description
NDF-RT
N0000182137
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY Cytochrome P450 2D6 Inhibitors [MoA]
MERCK INDEX
m11844
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY
NCI_THESAURUS
C97952
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY
ChEMBL
CHEMBL3707331
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY
EPA CompTox
DTXSID90203740
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY
DRUG BANK
DB09291
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY
FDA UNII
NLE429IZUC
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY
DAILYMED
NLE429IZUC
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY
INN
8882
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY
PUBCHEM
10311306
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY
DRUG CENTRAL
5027
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY
RXCUI
1665496
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY RxNorm
SMS_ID
100000144489
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY
EVMPD
SUB121121
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY
USAN
CD-170
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY
CAS
552292-08-7
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY
IUPHAR
5749
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY
NDF-RT
N0000190113
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY Breast Cancer Resistance Protein Inhibitors [MoA]
CHEBI
90908
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY
WIKIPEDIA
Rolapitant
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY
NDF-RT
N0000185503
Created by admin on Fri Dec 15 15:34:23 GMT 2023 , Edited by admin on Fri Dec 15 15:34:23 GMT 2023
PRIMARY P-Glycoprotein Inhibitors [MoA]
Related Record Type Details
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
SUBSTANCE-P RECEPTOR
TARGET -> INHIBITOR
ANTAGONIST
Ki
Structure of ROLAPITANT
EXCRETED UNCHANGED->SUBSTANCE
The total of 46% of the radioactive dose was recovered in urine and feces.In the pooled feces 37.8% of the dose was recovered. Rolapitant was the most prominent component accounting for 12.7% of the dose
MAJOR
FECAL
Structure of ROLAPITANT HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Structure of ROLAPITANT HYDROCHLORIDE ANHYDROUS
SALT/SOLVATE -> PARENT
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> NON-SUBSTRATE
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> INHIBITOR
[I]/IC50 value for p-gp inhibition was estimated to be 0.23. Based on [I]/IC50 > 0.1 a potential in-vivo drug interaction via inhibition of p-gp cannot be ruled out.
INHIBITOR
IC50
CYTOCHROME P450 2D6
METABOLIC ENZYME -> INHIBITOR
COMPETITIVE INHIBITOR
Ki
Related Record Type Details
Structure of SCH-720881
METABOLITE ACTIVE -> PARENT
The metabolite SCH 720881 (M19) which accounted 25% of the increased exposure to total plasma radioactivity was identified as a major circulating metabolite of rolapitant.
MAJOR
PLASMA
Related Record Type Details
Structure of ROLAPITANT
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966